An index for staging facial lipoatrophy and evaluation of the efficacy of the treatment with polymethylmethacrylate in HIV/AIDS patients: A pilot study

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 8, 2013, Pages 990-996

  Serra, M S ^a   Oyafuso, L K ^b   Trope, B M ^a   Munhoz Leite, O H ^c   Ramos E Silva, M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Emilio Ribas Infectious Disease Hospital   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FILLER; POLY(METHYL METHACRYLATE);

ADULT; AIDS PATIENT; ARTICLE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; EDEMA; FACIAL LIPOATROPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIPOATROPHY; MALE; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; FACE; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMETHYL METHACRYLATE; TREATMENT OUTCOME;

EID: 84880513825     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04632.x     Document Type: Article

References (14)

1. Carr A, Samaras K, Burton S, Freund J, Chisholm DJ, Cooper DA,. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitor. AIDS 1998; 12: F51-F58.
2. Amard P, Saint-Marc T, Katz P,. The effects of polylactic acid as therapy foor lipoatrophy of the face. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; Toronto, 2000 [abstract P94]. Antivir Ther 2000; 5 (Suppl. 5): 79.
3. Serra M,. Risk factors for lipodystrophy and impact on the quality of life after treatment with methacrylate. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; Toronto, 2000 [abstract P76]. Antivir Ther 2000; 5 (Suppl. 5): 68.
4. Barton SE, Engelhard P, Conant M,. Poly-L-lactic acid treating HIV-associated facial lipoatrophy: a review of clinical studies. Int J STD AIDS 2006; 17: 429-435.
5. Hanke CW, Redbord KP,. Safety and efficacy of poli-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs in Dermatol 2007; 6: 123-128.
6. Casavantes LC,. Biopolímero polialquilamida (Bio-Alcamid TM), material de relleno de alto volumen para la reconstrucciõn facial en pacientes con lipoatrofia asociada a VIH Presentaciõn de 100 casos. Dermatología CMQ 2004; 2: 226-233.
7. Serra M,. Facial implants with polymethylmethacrylate (PMMA) for lipodystrophy correction: 36 months follow up. XIV International AIDS Conference. [Abstract ThPeB 7378] Barcelona Jul 2002.
8. Sutinen J,. Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr Opin Infect Dis 2005; 8: 25-33.
9. Serra MS, Oyafuso LK, Trope BM,. Polymethylmethacrylate (PMMA) for facial atrophy treatment: 5 years follow-up. Presented at the XV International AIDS Conference, [abstract MoOrB1060] Bangkok, Thailand, July 11-16, 2004.
10. Arakaki D, Lima JN, Trope BM, et al. Characterization and quantification of the facial lipoatrophy due to HAART based on the facial lipoatrophy severity index. XV International AIDS Conference, [abstract B 11932] Bangkok, Thailand, July 11-16, 2004.
11. Serra M, Oyafuso LKM,. Lipoatrophy severity index: a quantitative score for facial atrophy to evaluate treatment with polymethylmethacrylate, 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Paris, Jul 2003 [Abstract 117]. Antivir Ther 2003; 8: L78.
12. Ministério da Saúde do Brasil. Programa Nacional em DST/AIDS. Brasília. Portaria Conjunta SAS;SVS n o 1, de 20 de janeiro de 2009, disponível em www.aids.gov.br. Last viewed April 30 2010.
13. James J, Carruthers A, Carruthers J,. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28: 979-986.
14. Casavantes LC,. Consideraciones clínicas de la lipoatrofia facial asociada a infecciõn por HIV. Dermatología CMQ 2004; 2: 218-223.